Welcome to our dedicated page for ImageneBio SEC filings (Ticker: IMA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
ImageneBio, Inc. filings document a Nasdaq-listed biotechnology issuer focused on IMG-007, its anti-OX40 receptor antagonist program for autoimmune and inflammatory diseases. Its 8-K reports disclose operating results, program updates, Regulation FD materials, private-placement and capital-structure matters, and officer or director changes.
Proxy materials cover annual meeting proposals, director elections, auditor ratification, equity incentive plan amendments, and executive compensation governance. The filing record also identifies the company’s common stock on The Nasdaq Capital Market and records formal disclosures tied to its completed reverse-merger corporate history.
ImageneBio filed a Rule 424(b)(3) prospectus supplement to its Form S-1, relating to the proposed offer and resale from time to time by selling stockholders of 2,508,337 shares of common stock. The supplement updates the prospectus with information from a Current Report on Form 8-K. The company’s common stock trades on Nasdaq as “IMA,” and the last reported sales price was $8.24 per share on November 4, 2025.
The attached 8-K reports the Board increased its authorized size from six to seven directors and appointed Joseph P. Slattery to the Board effective November 1, 2025, and as Chair of the Audit Committee effective November 18, 2025. The company entered into its standard indemnification agreement with Mr. Slattery.
ImageneBio, Inc. expanded its Board of Directors from six to seven and appointed Joseph P. Slattery as a director effective November 1, 2025. He will serve as Chair of the Audit Committee effective November 18, 2025.
The company entered into its standard indemnification agreement with Mr. Slattery in the form previously filed as Exhibit 10.10 to its Form S-1.
ImageneBio, Inc. filed a prospectus supplement covering the proposed offer and resale of 2,508,337 shares of common stock by selling stockholders. The supplement updates the base prospectus with recent disclosures and attaches three Current Reports on Form 8‑K.
- On October 10, 2025, CFO and principal financial officer Jotin Marango, M.D., Ph.D., resigned effective October 20, 2025; the resignation was not due to any disagreement.
- On October 21, 2025, the board appointed CEO Kristin Yarema, Ph.D., as interim principal financial officer, effective immediately.
- On October 23, 2025, the company elected not to automatically renew a transition services agreement with Miragene Inc. and extended a subset of services for six months; total fees for the extension services are $200,000.
The company’s common stock trades on Nasdaq as “IMA.” On October 29, 2025, the last reported sale price was $8.79 per share.
Imagenebio, Inc. (IMA) filed an 8-K stating it will not allow its transition services agreement with Miragene Inc. to automatically renew and will instead extend a subset of services for six months after the initial term. The Miragene Extension Services include chemistry, manufacturing and controls, as well as translational sciences research and support. Total fees payable to Miragene for the extension are $200,000, reflecting a limited, short-term continuation of select operational support.
ImageneBio, Inc. appointed its Chief Executive Officer, Kristin Yarema, Ph.D., as the company’s interim principal financial officer, effective immediately on October 21, 2025.
The board made the appointment to fill the finance leadership role on an interim basis. Dr. Yarema’s biographical information is incorporated by reference from the “Management” section of the company’s Form S-1 (File No. 333-290108) filed on September 8, 2025.
ImageneBio, Inc. reported that its Chief Financial Officer and principal financial officer, Jotin Marango, M.D., Ph.D., has submitted his resignation, effective October 20, 2025. The company states that his resignation is not due to any disagreement with the company. ImageneBio plans to conduct a search for a new chief financial officer to fill the role.
ImageneBio, Inc. reported that director Stephen Hui Wang acquired common stock on 07/25/2025 as part of a two-step merger that converted Legacy Inmagene preferred and ordinary shares into Issuer common stock at a ratio of 0.003051 per legacy share. The filing shows Mr. Wang's indirect holdings increased by 188,042 shares through entities he controls, plus additional indirect holdings of 50,144 and 12,535 shares via related vehicles. The transaction reflects the merger consideration and a corporate name change from Ikena Oncology, Inc. to ImageneBio, Inc.
The report discloses that the Form 4 was filed late due to delays obtaining EDGAR codes. The filing describes the chain of ownership: shares were received in exchange for Series C-1 and C-2 preferred shares of Legacy Inmagene, and voting/investment power over the reported holdings is exercised by Mr. Wang through HLC GP and affiliated entities.
ImageneBio, Inc. filed an Initial Statement of Beneficial Ownership (Form 3) for director Stephen Hui Wang relating to an event on 07/25/2025. The filing states that no securities are beneficially owned by the reporting person. The Form 3 was executed via Power of Attorney and signed by Erin Butler, Attorney-in-Fact on 10/10/2025. The filing notes it was submitted late due to delays obtaining the reporting person’s EDGAR codes.
ImageneBio, Inc. completed a reverse recapitalization through a merger with Ikena Oncology that resulted in ImageneBio as the public company and produced pro forma combined financial statements giving effect as if the transactions occurred on January 1, 2024. The company divested its Non-OX40 business to SellCo for a promissory note of $8.9 million that accrues interest at 4.61% and matures by 2035 or on earlier default triggers. The filing highlights one-time pro forma adjustments including $14.9 million of share-based compensation, other merger-related cash payments (severance/retention and D&O tail) and derecognition of certain deferred offering costs. Management warns of recurring losses and negative operating cash flows that raise substantial doubt about going concern and states additional capital will be required to advance IMG-007.
IMG-007 is a non-depleting anti-OX40 monoclonal antibody in Phase 2 development for moderate-to-severe atopic dermatitis. Clinical results disclosed include a Phase 1b/2a proof-of-concept with durable activity up to 24 weeks, an EASI-75 rate of 54% by Week 16 in a 13-patient cohort, favorable tolerability (no serious adverse events reported), target-mediated PK with projected therapeutic IV doses (300–600 mg) maintaining target levels for 18 weeks and mean terminal half-life ~31–35 days. The company discloses patent filings (U.S. and international) with expected patent expiration in 2041 and notes regulatory, manufacturing, intellectual property, litigation and reimbursement risks.
ImageneBio insider ownership updated after a corporate merger. The Form 4 reports that, as part of a two-step merger, legacy Inmagene ordinary and preferred shares were converted into Issuer common stock at a fixed exchange ratio, resulting in the reporting person receiving 143,832 shares directly and an indirect interest in 971,173 shares held by Engene Inc.
The transfers arose from the merger consideration exchanged for 47,142,857 Series Seed convertible preferred shares and 318,313,306 ordinary shares of legacy Inmagene, using a conversion factor of 0.003051 common shares per legacy share. The filer disclaims beneficial ownership of Engene Inc.'s shares except for any pecuniary interest; Engene Inc.'s sole shareholder is a trust for which reporting person's family are beneficiaries. The filing notes it was submitted late due to administrative delays.